Year: 2020

DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor conferences in November.Management will host investor meetings during the Jefferies Virtual London Healthcare Conference on Tuesday and Wednesday, November 17-18, 2020.Management will host investor meetings during A.G.P.’s Virtual Healthcare Symposium on Thursday, November 19, 2020.About Nabriva Therapeutics plcNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration...

– Patient enrollment in Phase 1/2 studies of EOS-850 A2AR antagonist and EOS-448 FCγR-enabled anti-TIGIT antibody continues with initial data expected in 1H21 – – Strong cash position to support ongoing clinical development and operations into 2023 –CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.“We are focused on advancing our two lead candidates, EOS-850, our adenosine A2A receptor antagonist, and EOS-448, our TIGIT antagonist, both now in Phase 1/2a...

GREENWICH, Conn., Nov. 12, 2020 (GLOBE NEWSWIRE) —  XPO Logistics, Inc. (NYSE: XPO), a leading global provider of supply chain solutions, has made extensive preparations for what could be a record holiday shopping season in many of the 30 countries where it operates. The company’s investments in supporting its e-commerce, retail and manufacturing customers during peak seasonality include:Expanded use of intelligent automation to enhance the speed, accuracy and safety of order fulfillment and reverse logistics processes, including the deployment of collaborative robots that work side-by-side with employees A major recruitment effort aimed at filling over 25,000 job openings in the fourth quarter Substantial logistics and freight capacity, including approximately 200 million square feet of warehouse space globally and access to integrated...

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — Mission Ready Solutions Inc. (“Mission Ready” or the “Company”) (TSX Venture: MRS) is pleased to announce the appointment of William J. Bratton to the Board of Directors of the Company (the “Board”), effective immediately.During a 46-year career in law enforcement, Commissioner Bratton instituted progressive change while leading six police departments, including seven years as Chief of the Los Angeles Police Department and two nonconsecutive terms as the Police Commissioner of the City of New York. He is the only person ever to lead the police agencies of America’s two largest cities.Commissioner Bratton was the 42nd police commissioner of the City of New York from January 2014 to September 2016. It was the second time he had held the post. During that time, he oversaw...

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that preclinical data on BCX9930, an oral Factor D inhibitor, will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting being held as a virtual event, December 5-8, 2020.The abstract is available on the ASH website at www.hematology.org.Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH); Poster #1680, Sunday, December 6, 2020, 10:00 a.m. – 6:30 p.m. ETAbout BCX9930Discovered by BioCryst, BCX9930 is a novel, oral, potent and selective small molecule inhibitor of Factor D currently in Phase 1 clinical development for the treatment of complement-mediated...

 Preliminary Q3 2020 results and quarterly cash dividend of $0.15 per share Hamilton, Bermuda, November 12, 2020. SFL Corporation Ltd. (“SFL” or the “Company”) today announced its preliminary financial results for the quarter ended September 30, 2020.Highlights67th consecutive quarterly dividend declared, $0.15 per shareOperating revenue of $116 million, and net income of $16 million in the third quarterReceived charter hire1 of approximately $157 million in the quarter from the Company’s vessels and rigs, including $5.7 million of profit shareAdjusted EBITDA2 of $93 million from consolidated subsidiaries, plus an additional $24.4 million adjusted EBITDA2 from wholly owned non-consolidated subsidiariesCash and cash equivalents of approximately $206 million, excluding $22 million of cash in wholly owned non-consolidated subsidiariesOle...

Selskabsmeddelelse nr. 2020/15Fynske Bank bag solidt kvartalsregnskabRegnskabet for 1.-3. kvartal 2020 viser et fornuftigt resultat før skat på 30,3 mio. kroner.Fynske Bank kommer ud af årets tre første kvartaler med et fornuftigt resultat trods den globale uro som følge af COVID-19.Regnskabet for 1.-3. kvartal 2020 viser således et overskud på 30,3 mio. kr. før skat. Sammenlignet med samme periode sidste år er der tale om en tilbagegang fra 75,9 mio. kr. før skat. Men adm. direktør Petter Blondeau peger på, at resultatet er ganske fornuftigt set i lyset af den nuværende markedssituation og med bankens forsigtighedsprincip ift. COVID-19-relaterede nedskrivninger.”På positivsiden kan vi notere os en tilfredsstillende tilgang af nye kunder, og generelt har Fynske Bank en rigtig stærk kapital- og likviditetsposition i et marked, som helt...

ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The size of the offering was increased from the previously announced $200.0 million aggregate principal amount of notes. In connection with the offering, Esperion also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $30.0 million aggregate principal amount of the notes. The sale of the notes is expected to settle on November...

–  Submitted CTA for INZ-701 for the treatment of ENPP1 deficiency to United Kingdom regulatory agency ––  Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency ––  Expect to initiate INZ-701 Phase 1/2 clinical trials for ENPP1 and ABCC6 deficiencies in first half of 2021 –BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.“ENPP1 deficiency is a systemic, progressive and continuous disease occurring over the course of a patient’s lifetime, starting as...